Innorna Secures FDA Clearance for Phase 1 mRNA Therapy in Refractory Gout

Mar 17, 2026-

Innorna has received U.S. FDA clearance to initiate a Phase 1 clinical trial evaluating an investigational mRNA therapy for refractory gout, marking an important step in expanding mRNA technology into chronic disease treatment. The study will explore whether mRNA therapeutics, delivered via lipid nanoparticles (LNPs), can achieve sufficient safety and durability for repeated dosing in a common condition.

Innorna’s experimental therapy uses mRNA to encode uricase, an enzyme that breaks down uric acid in the liver—the underlying cause of gout. By enabling the body to produce the enzyme internally, the approach aims to provide a more convenient alternative to existing treatments such as Krystexxa, which requires biweekly infusions. The company believes its therapy could potentially be administered once per month, although detailed trial design information has not yet been disclosed.

The Phase 1 trial will primarily assess safety, tolerability, and biological activity, representing a critical test for the broader mRNA field. While mRNA has demonstrated success in vaccines, its application in chronic diseases has been limited by challenges such as short-lived expression and immune responses to repeated LNP dosing. Addressing these barriers will be essential for enabling long-term therapeutic use.

Innorna attributes its progress to a proprietary platform built on a large library of ionizable lipids, key components of LNP delivery systems. The company has synthesized more than 6,000 ionizable lipids and screened approximately 2,000 in preclinical models to optimize delivery efficiency and safety. According to CEO Linxian Li, who previously conducted research in Robert Langer’s lab at MIT, advances in lipid design have significantly improved tolerability compared to earlier generations.

The program emerges during a challenging period for mRNA therapeutics in the United States, where investment has slowed, but innovation continues globally. China-based biotechs, including CirCode Biomed and RiboX Therapeutics, are advancing next-generation RNA platforms such as circular RNA, reflecting a broader push to expand RNA-based medicines into new therapeutic areas.

Founded in 2019, Innorna has raised approximately $150 million to support its platform and pipeline development. In addition to its gout program, the company is advancing an RSV mRNA vaccine in Phase 2 trials in China and a shingles vaccine in Phase 2 studies in the United States. With operations centered in Shenzhen and additional presence in Boston, San Diego, and Hong Kong, Innorna continues to position itself as a growing player in the global mRNA therapeutics landscape.